ECONOMIC EVALUATION OF SUNITINIB MALATE FOR THE FIRST-LINE TREATMENT OF METASTARIC RENAL CELL CARCINOMA IN THE CHINESE HEALTH CARE SETTING

被引：0
|
作者：
Wu, J. [1 ]
Zhang, N. [1 ]
Dong, P. [2 ]
机构：
[1] Tianjin Univ, Tianjin 300072, Peoples R China
[2] Pfizer China, Beijing, Peoples R China
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.1209
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A454 / A454
页数：1
相关论文
共 50 条
  • [1] Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma
    Remak, Edit
    Charbonneau, Claudie
    Negrier, Sylvie
    Kim, Sindy T.
    Motzer, Robert J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (24) : 3995 - 4000
  • [2] Economic Evaluation of Sunitinib Malate for the First-Line Treatment of Metastatic Renal Cell Carcinoma Comment
    Penson, David F.
    [J]. JOURNAL OF UROLOGY, 2009, 181 (03): : 1067 - 1067
  • [3] PHARMACOECONOMIC EVALUATION OF SUNITINIB MALATE FOR FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN MEXICO
    Tenorio, C.
    Vargas, J.
    Rizo-Rios, P.
    Flores-Gil, O.
    Martinez-Fonseca, J.
    Mould-Quevedo, J.
    Davila-Loaiza, G.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A44 - A45
  • [4] ECONOMIC EVALUATION OF SUNITINIB AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA IN COLOMBIA
    Prieto, V. A.
    Reyes, J. M.
    Lopez-Cabra, C.
    Diaz, J. A.
    Urrego-Novoa, J. R.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A149 - A149
  • [5] Economic evaluation of sunitinib as first-line treatment for metastatic renal cell carcinoma in Mexico
    Emilio, Mucino-Ortega
    Joaquin Federico, Mould-Quevedo
    [J]. GACETA MEXICANA DE ONCOLOGIA, 2010, 9 (02): : 48 - 57
  • [6] ECONOMIC EVALUATION OF SUNITINIB FOR THE FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN RUSSIAN FEDERATION
    Yagudina, R.
    Kulikov, A.
    Novikov, I
    [J]. VALUE IN HEALTH, 2012, 15 (04) : A222 - A222
  • [7] Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland
    Purmonen, Timo
    Martikainen, Janne A.
    Soini, Erkki J. O.
    Kataja, Vesa
    Vuorinen, Riikka-Liisa
    Kellokumpu-Lehtinen, Pirkko-Liisa
    [J]. CLINICAL THERAPEUTICS, 2008, 30 (02) : 382 - 392
  • [8] Patterns of care in renal cell carcinoma: Comparison of treatment duration for first-line sunitinib and pazopanib
    Garofalo, David
    Montgomery, Jim
    Drenning, Jason
    Feinberg, Bruce A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] Economic Evaluation of Everolimus versus Sorafenib for the Treatment of Metastatic Renal Cell Carcinoma after Failure of First-Line Sunitinib
    Casciano, Roman
    Chulikavit, Maruit
    Di Lorenzo, Giuseppe
    Liu, Zhimei
    Baladi, Jean-Francois
    Wang, Xufang
    Robertson, Justin
    Garrison, Lou
    [J]. VALUE IN HEALTH, 2011, 14 (06) : 846 - 851
  • [10] Sunitinib First-line Treatment in Metastatic Renal Cell Carcinoma: Costs and Effects
    Vuorinen, Riikka-Liisa
    Paunu, Niina
    Turpeenniemi-Hujanen, Taina
    Reunamo, Taina
    Jekunen, Antti
    Kataja, Vesa
    Sintonen, Harri
    Purmonen, Timo
    Kellokumpu-Lehtinen, Pirkko-Liisa
    [J]. ANTICANCER RESEARCH, 2019, 39 (10) : 5559 - 5564
12345